Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Den direkte orale antikoagulering versus warfarin efter hjertekirurgi (DANCE)

15. september 2026 opdateret af: Population Health Research Institute

The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Detaljeret beskrivelse

Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.

Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.

In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.

The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.

A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

3500

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Victoria
      • Fitzroy, Victoria, Australien, 3065
        • Rekruttering
        • St Vincent's Hospital Melbourne
        • Kontakt:
          • Andrew Newcomb, MD
        • Ledende efterforsker:
          • Andrew Newcomb, MD
      • Parkville, Victoria, Australien, 3050
        • Ikke rekrutterer endnu
        • Royal Melbourne Hospital, University of Melbourne
        • Kontakt:
          • Alistair Royse, MD
        • Ledende efterforsker:
          • Alistair Royse, MD
    • Alberta
      • Edmonton, Alberta, Canada, T6G 2C8
        • Rekruttering
        • University of Alberta Hospital
        • Ledende efterforsker:
          • Steven Meyer, MD
        • Kontakt:
          • Steven Meyer, MD
    • British Columbia
      • Vancouver, British Columbia, Canada, V6T 1Z3
        • Rekruttering
        • University of British Columbia
        • Ledende efterforsker:
          • Erica Wang, PharmD
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • Rekruttering
        • St. Boniface Hospital
        • Ledende efterforsker:
          • Michael Yamashita, MD
        • Kontakt:
          • Michael Yamashita, MD
    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L4L2
        • Aktiv, ikke rekrutterende
        • Saint John Regional Hospital
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
        • Rekruttering
        • Health Science Centre
        • Ledende efterforsker:
          • Hasib Hanif, MD
    • Ontario
      • Greater Sudbury, Ontario, Canada, P3E 5J1
        • Rekruttering
        • Health Sciences North Research Institute
        • Ledende efterforsker:
          • Bindu Bittira, MD
      • Hamilton, Ontario, Canada, L8L 2X2
        • Rekruttering
        • Hamilton General Hospital
        • Kontakt:
      • Toronto, Ontario, Canada, M5G 2C4
        • Rekruttering
        • Toronto General Hospital
        • Kontakt:
          • Vivek Rao, MD
        • Ledende efterforsker:
          • Vivek Rao, MD
      • Toronto, Ontario, Canada, M4N 3M5
        • Rekruttering
        • Sunnybrook Hospital
        • Kontakt:
          • Stephen Fremes, MD
        • Ledende efterforsker:
          • Stephen Fremes, MD
    • Quebec
      • Montreal, Quebec, Canada, H1T 1C8
        • Rekruttering
        • Montreal Heart Institute
        • Kontakt:
          • Philippe Demers, MD
        • Ledende efterforsker:
          • Philippe Demers, MD
      • Montreal, Quebec, Canada, H4J1C5
        • Rekruttering
        • Hôpital Sacré-Coeur de Montréal
        • Ledende efterforsker:
          • Hugues Jeanmart, MD
        • Kontakt:
          • Hugues Jeanmart, MD
      • Québec, Quebec, Canada, G1V 4G5
        • Rekruttering
        • IUCPQ-ULaval
        • Kontakt:
          • Eric Dumont, MD
        • Ledende efterforsker:
          • Eric Dumont, MD
      • Bonn, Tyskland, 53127
        • Aktiv, ikke rekrutterende
        • University Hospital Bonn Heart Center
      • Essen, Tyskland, 45147
        • Ikke rekrutterer endnu
        • West-German Heart and Vascular Center, University of Duisburg-Essen
        • Kontakt:
          • Matthias Thielmann, MD, PhD
        • Ledende efterforsker:
          • Matthias Thielmann, MD, PhD
      • Hamburg, Tyskland, 20246
        • Rekruttering
        • University Medical Center Hamburg-Eppendorf
        • Kontakt:
          • Simon Pecha, MD
        • Ledende efterforsker:
          • Simon Pecha, MD
    • Saxony
      • Leipzig, Saxony, Tyskland, 04289
        • Aktiv, ikke rekrutterende
        • Heart Center Leipzig
    • Thuringia
      • Jena, Thuringia, Tyskland, Germany
        • Rekruttering
        • University Hospital Jena
        • Kontakt:
          • Torsten Doenst, MD, PhD
        • Ledende efterforsker:
          • Torsten Doenst, MD, PhD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥18 years at the time of enrolment,
  2. Open heart surgery in the last 10 days,
  3. Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
  4. Informed consent from either the patient or a substitute decision-maker.

Exclusion Criteria:

  1. Mechanical valve replacement,
  2. Antiphospholipid syndrome (triple positive),
  3. Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
  4. Known significant liver disease (Child-Pugh classification B and C),
  5. Left ventricular thrombus,
  6. Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
  7. Known contraindication for any DOAC or VKA,
  8. Women who are pregnant, breastfeeding, or of childbearing potential,
  9. Surgery including left ventricular assist device implantation or cardiac transplantation,
  10. Previously enrolled in this trial,
  11. Follow-up not possible,
  12. History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Faktoriel opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Direct Oral Anticoagulation (DOAC)

Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.

Andre navne:
  • Apixaban
  • Dabigatran
  • Edoxaban
  • Rivaroxaban
Placebo komparator: Vitamin K Antagonist

Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.

Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.

Andre navne:
  • Warfarin

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Major Bleeding
Tidsramme: 30-Days post-randomization

Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis)

30-Days post-randomization

Sekundære resultatmål

Resultatmål
Tidsramme
Sammensat af slagtilfælde og systemisk arteriel emboli uden for centralnervesystemet efter 30 og 90 dage.
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Større blødning
Tidsramme: 90 dage efter randomisering
90 dage efter randomisering
Pleural eller perikardiel effusion, der kræver dræning
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Systemisk arteriel emboli
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Iskæmisk slagtilfælde
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Dyb venetrombose
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Lungeemboli
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Varigheden af ​​postoperativ indlæggelse
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Dødelighed af alle årsager
Tidsramme: 6 måneder efter randomisering
6 måneder efter randomisering

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Myokardieinfarkt
Tidsramme: 30-dage og 90-dage efter randomisering
30-dage og 90-dage efter randomisering
Sammenhæng mellem subklinisk klapthrombose og klinisk signifikant aortaklaptrombose, slagtilfælde eller systemisk emboli
Tidsramme: 90 dage
90 dage
Minor Bleeding
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All bleeding (major plus minor)
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
Valve Thrombosis
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
Hemorrhagic stroke
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All Stroke
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome

30-Days and 90-Days post-randomization
All Arterial Thrombosis/thromboembolism
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis

30-Days and 90-Days post-randomization
Quality of Life - EQ-5D-5L
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome: Measured by The EQ-5D-5L Questionnaire

30-Days and 90-Days post-randomization
Patient Satisfaction with Anticoagulant treatment
Tidsramme: 30-Days and 90-Days post-randomization

Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire

30-Days and 90-Days post-randomization
Subclinical Valve Thrombosis on CT scan
Tidsramme: 60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization
Mean Aortic Valve g=Gradient on echocardiogram
Tidsramme: 60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization
Aortic Valve Reintervention
Tidsramme: 60 to 90-Days post-randomization

Substudy outcome

60 to 90-Days post-randomization

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Emilie Belley-Cote, MD, MSc, McMaster University

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

18. juli 2021

Primær færdiggørelse (Anslået)

1. juni 2027

Studieafslutning (Anslået)

1. juni 2027

Datoer for studieregistrering

Først indsendt

24. februar 2020

Først indsendt, der opfyldte QC-kriterier

24. februar 2020

Først opslået (Faktiske)

26. februar 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

15. september 2026

Sidst verificeret

1. september 2025

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner